Danvatirsen

N/A

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameDanvatirsen
Drug Alias NameIONIS-STAT3-2.5RxIONIS-STAT3RxISIS-STAT3RxISIS-481464ISIS-345794 +[8] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionSignal transducer and activator of transcription 3 inhibitors
TargetsSignal transducer and activator of transcription 3
Therapy Area/IndicationsMismatch Repair Deficient CancerAscitesCarcinoma, Non-Small-Cell Lung +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc
Inactive CompaniesFlamingo Therapeutics NVNational Cancer InstituteMedimmune Llc +[4] 
Active IndicationsMismatch Repair Deficient CancerCarcinoma, Non-Small-Cell LungLung Neoplasms +[6] 
Inactive IndicationsAscitesOvarian NeoplasmsGastrointestinal Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A